MARKET

NLTX

NLTX

Neoleukin Therapeutics Inc
NASDAQ
0.6780
-0.0108
-1.57%
After Hours: 0.6780 0 0.00% 16:02 09/26 EDT
OPEN
0.6681
PREV CLOSE
0.6888
HIGH
0.7091
LOW
0.6500
VOLUME
172.60K
TURNOVER
0
52 WEEK HIGH
8.01
52 WEEK LOW
0.6500
MARKET CAP
28.87M
P/E (TTM)
-0.6063
1D
5D
1M
3M
1Y
5Y
Neoleukin draws double downgrade at BofA on limited near-term upside
Bank of America downgraded immunotherapy-focused Neoleukin Therapeutics, Inc. (NASDAQ:<a href="https://seekingalpha.com/symbol/NLTX?utm_medium=referral&utm_source=webull.com" title="Neoleukin Therapeutics, Inc."...
Seekingalpha · 09/12 19:32
B of A Securities Downgrades Neoleukin Therapeutics to Underperform, Announces $1 Price Target
B of A Securities analyst Greg Harrison downgrades Neoleukin Therapeutics (NASDAQ:NLTX) from Buy to Underperform and announces $1 price target.
Benzinga · 09/12 13:42
HC Wainwright Cuts Price Target On This Stock By 73%, Also Check Out Other Major PT Changes Here
Susquehanna cut the price target on Baidu, Inc. (NASDAQ: BIDU) from $200 to $195. Susquehanna analyst Shyam Patil maintained the stock with a Positive rating. Baidu shares rose 0.7% to $139.38 in pre-market trading.
Benzinga · 09/12 12:44
--BofA Securities Downgrades Neoleukin Therapeutics to Underperform From Buy, Adjusts Price Target to $1 From $3
--BofA Securities Downgrades Neoleukin Therapeutics to Underperform From Buy, Adjusts Price Target to $1 From $3
MT Newswires · 09/12 11:06
HC Wainwright & Co. Maintains Buy on Neoleukin Therapeutics, Lowers Price Target to $6
HC Wainwright &amp; Co. analyst Robert Burns maintains Neoleukin Therapeutics (NASDAQ:NLTX) with a Buy and lowers the price target from $22 to $6.
Benzinga · 09/12 10:31
HC Wainwright Adjusts Neoleukin Therapeutics' Price Target to $6 from $22, Maintains Buy Rating
HC Wainwright Adjusts Neoleukin Therapeutics' Price Target to $6 from $22, Maintains Buy Rating
MT Newswires · 09/12 08:21
Li Auto, Haleon, Sibanye Stillwater among premarket losers' pack
Turquoise Hill Resources TRQ -18% after <a href="https://seekingalpha.com/news/3872769-turquoise-hill-rejects-rio-tintos-bid-to-take-control-of-huge-mongolia-mine?utm_medium=referral&utm_source=webull.com" target="_...
Seekingalpha · 08/15 12:50
ARVL, ASTS and SDC are among pre market gainers
Neptune Wellness Solutions (NEPT) +48%. ADDvantage Tech...
Seekingalpha · 08/12 12:31
More
About NLTX
Neoleukin Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in providing immunotherapies for cancer, inflammation, and autoimmunity using de novo protein design technology. The Company's lead product candidate, NL-201, is an interleukin-2 (IL-2)/ interleukin-15 (IL-15) immunotherapy designed to eliminate binding to the alpha subunit of the IL-2 receptor (also known as CD25) while enhancing binding to the beta and gamma subunits. NL-201 is designed to mimic the therapeutic activity of the cytokines IL-2 and IL-15 for the treatment of various types of cancer, including renal cell carcinoma (RCC), melanoma and hematological malignancies. Its Neoleukin platform uses a set of advanced computational algorithms and methods to design functional de novo proteins. NL-201 holds promise in combination with cell therapy to expand and maintain populations of transplanted CAR-T and natural killer (NK) cells.

Webull offers kinds of Neoleukin Therapeutics Inc stock information, including NASDAQ:NLTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NLTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NLTX stock methods without spending real money on the virtual paper trading platform.